Logo image of RSLS

RESHAPE LIFESCIENCES INC (RSLS) Stock Fundamental Analysis

NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD

5.12  -0.8 (-13.51%)

After market: 5.1001 -0.02 (-0.39%)

Fundamental Rating

1

Taking everything into account, RSLS scores 1 out of 10 in our fundamental rating. RSLS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. RSLS has a bad profitability rating. Also its financial health evaluation is rather negative. RSLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RSLS had negative earnings in the past year.
In the past year RSLS has reported a negative cash flow from operations.
In the past 5 years RSLS always reported negative net income.
RSLS had a negative operating cash flow in each of the past 5 years.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RSLS has a Return On Assets of -148.76%. This is amonst the worse of the industry: RSLS underperforms 89.42% of its industry peers.
Industry RankSector Rank
ROA -148.76%
ROE N/A
ROIC N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K 3K

1.3 Margins

The Gross Margin of RSLS (63.17%) is better than 62.96% of its industry peers.
RSLS's Gross Margin has improved in the last couple of years.
RSLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
RSLS has more shares outstanding than it did 1 year ago.
RSLS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RSLS has a worse debt to assets ratio.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RSLS has an Altman-Z score of -182.81. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
RSLS has a worse Altman-Z score (-182.81) than 97.35% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -182.81
ROIC/WACCN/A
WACC9.08%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RSLS has a Current Ratio of 0.92. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
RSLS's Current ratio of 0.92 is on the low side compared to the rest of the industry. RSLS is outperformed by 91.53% of its industry peers.
RSLS has a Quick Ratio of 0.92. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.43, RSLS is doing worse than 93.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.43
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for RSLS have decreased strongly by -45.83% in the last year.
Looking at the last year, RSLS shows a decrease in Revenue. The Revenue has decreased by -7.79% in the last year.
RSLS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.54% yearly.
EPS 1Y (TTM)-45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.41%
Revenue 1Y (TTM)-7.79%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-8.93%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RSLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

RSLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (5/21/2025, 8:00:01 PM)

After market: 5.1001 -0.02 (-0.39%)

5.12

-0.8 (-13.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-12 2025-08-12
Inst Owners4.1%
Inst Owner Change442.55%
Ins Owners5.18%
Ins Owner Change0%
Market Cap57.75M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.31%
Min Revenue beat(2)-44.22%
Max Revenue beat(2)-10.4%
Revenue beat(4)0
Avg Revenue beat(4)-19.2%
Min Revenue beat(4)-44.22%
Max Revenue beat(4)-9.41%
Revenue beat(8)0
Avg Revenue beat(8)-15.86%
Revenue beat(12)0
Avg Revenue beat(12)-16.28%
Revenue beat(16)0
Avg Revenue beat(16)-14.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.67
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS0.71
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -148.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.17%
FCFM N/A
ROA(3y)-223.45%
ROA(5y)-181.34%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y44.4%
F-Score3
Asset Turnover1.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.43
Altman-Z -182.81
F-Score3
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)11.32%
Cap/Depr(5y)20.35%
Cap/Sales(3y)0.55%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.41%
EPS Next Y20%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.79%
Revenue growth 3Y-16.19%
Revenue growth 5Y19.54%
Sales Q2Q%-8.93%
Revenue Next Year20%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.9%
OCF growth 3YN/A
OCF growth 5YN/A